From the publishers of JADPRO

Multiple Myeloma Resource Center

Advertisement
FROM THE EDITOR

Welcome to the Multiple Myeloma Resource Center! Here you’ll find current information, news items, highlights from the literature, and other resources that focus on multiple myeloma and the advanced practitioner’s role in delivering high-quality care to our patients. We’re excited to provide this information to you and your colleagues and hope this site is helpful to your practice. If you have any feedback or questions, please contact jadpro-editor@broadcastmed.com.

Charise Gleason, MSN, NP-C, AOCNP
Director and Chief of APPs at Winship Cancer Institute of Emory University
Nell Hodgson Woodruff School of Nursing at Emory Healthcare

News & Literature Highlights

Blood Advances (2024) 8 (1): 236–247.

Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups

Blood (2023) 142 (Supplement 1): 4705

Real-world outcomes for relapsed or refractory multiple myeloma patients treated with lenalidomide and daratumumab sparing triplet regimens: a United States retrospective cohort study

Blood (2023) 142 (Supplement 1): 4693

Cell-free DNA from blood or bone marrow as alternatives to bone marrow cells for molecular diagnostics and monitoring of multiple myeloma

Leukemia

Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma

Indian Journal of Cancer

Second stem cell transplantation for treatment of relapsed/refractory multiple myeloma after first autologous stem cell transplant: A 15-year retrospective institutional analysis

Cureus

Explosive disease progression after single-agent b-cell maturation antigen-targeted treatment in multiple myeloma: A report of three cases in Sheikh Shakhbout Medical City

The Lancet. Haematology

Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial

Journal of Chemotherapy

Varicella zoster virus reactivation reported with isatuximab use

Cancer Discovery

CAR T-cell availability for multiple myeloma improving but still limited

Platelets

Multiple myeloma and its treatment contribute to increased platelet reactivity

Advertisement
Advertisement